Shenzhen Kangtai Biological Products (300601)
- 12.67
- +0.46+3.77%
Shenzhen Kangtai Biological Products (300601) News
CITIC Securities Q1 Vaccine Industry Overview: Product Batch Release Volumes Up Year-on-Year; Multiple Products and New Indications Approved
In Q1 2026, the vaccine industry recorded a total of 875 batch releases, an increase of 14.1% year-over-year, primarily driven by substantial growth in batch releases of polio vaccines, measles-mumps-rubella (MMR) vaccines, and hepatitis vaccines.
Why Is the Vaccine Leader Acquiring a Shell Company with Unpaid Capital from Its Executive for 'Zero Yuan'? | Quick Read of Announcement
① Kangtai Bio received a zero-yuan transfer of 51% equity in Beijing Kunyuan, with all counterparties being the company's chairman, president, and other senior executives, as well as their related parties; ② The transferred equity corresponds to zero paid-in capital, and although Kangtai Bio did not pay any consideration, it is obligated to fulfill a subscribed capital contribution of RMB 51 million; ③ The target company was established only three months ago, has no available financial data, and has not disclosed any actual operations, pipeline products, technical patents, or other achievements.
Kangtai Biological (300601.SZ) 2025 Annual Profit Distribution: RMB 0.35 per 10 shares
Gelonghui, June 3 — Kangtai Biological Products Co., Ltd. (SZSE: 300601) announced its 2025 annual profit distribution implementation notice. The company’s 2025 annual profit distribution plan is as follows: based on the total number of shares outstanding on the record date specified in the announcement, a cash dividend of RMB 0.35 (tax inclusive) will be distributed for every 10 shares to all shareholders. The record date for this profit distribution is June 10, 2026, and the ex-dividend date is June 11, 2026.
A-share market movement | The Hantavirus outbreak draws attention! The virus prevention and treatment sector collectively surged, with Wantai Biotech up 9% and BGI Genomics rising over 5%.
Gelonghui, May 11 | Virus prevention and control concept stocks collectively rose in the A-share market. Among them, Walvax Biotech surged 19%, Capricorn Bio-Tech increased by over 15%, Daan Gene hit a 10% price limit, Wantai BioPharm gained 9%, Kangtai Biological Products rose over 8%, Zhifei Biological Products climbed 7%, and Frontier Biopharma-U, Probiotics Pharmaceuticals, CanSino Biologics, Wondfo Biotech, and Kanghua Biological Products increased by over 6%. Additionally, Jindike Biologics, BGI Group, Sichuan Maik Biotechnology, and TopRim Pharmaceuticals saw gains exceeding 5%. In terms of news, the cruise ship 'Hondeus' recently reported an outbreak of Hantavirus. Furthermore, a fatal case of Hantavirus was reported in Taipei City, Taiwan, related to infections carried by rats, drawing significant public attention.
KANGTAI BIOLOGICAL(300601): R&D PIPELINE CONTINUES TO PROGRESS; OVERSEAS BUSINESS ACHIEVES SIGNIFICANT GROWTH
Key takeaway: The company released its 2025 annual report and 1Q26 results.
Kangtai Bio (300601): Continuous advancement in the R&D pipeline, overseas business achieves rapid growth.
Key insights: The company released its 2025 annual report and Q1 2026 earnings report. In 2025, sales revenue remained robust, with new products such as the human diploid rabies vaccine and varicella vaccine continuing to gain market traction. Multiple vaccine products received regulatory approval for market entry. Q1 2026 was impacted by R&D expenses.
Kangtai Bio (300601): Stable Revenue Growth with a Rich Product Pipeline
Key investment highlights: Steady growth in revenue, with continued pressure on profits. In 2025, the company achieved operating revenue of 2.673 billion yuan (an increase of 0.81% year-on-year), net profit attributable to shareholders of 70 million yuan (a decrease of 65.12% year-on-year), and non-recurring net profit attributable to shareholders...
Shenzhen Kangtai Biological Products Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Kangtai Bio (300601): Stable revenue but pressured profits; anticipation for R&D progress
The company announced revenue, net profit attributable to shareholders, and non-recurring net profit of RMB 2.67 billion, RMB 0.7 billion, and RMB 0.7 billion respectively for 2025 (+1%/-65%/-70% year-on-year). The decline in profits was mainly due to the adjustment of the DTP immunization program affecting the tetravalent vaccine and operating costs.
Shenzhen Kangtai Biological Products: First Quarter Report 2026
Shenzhen Kangtai Biological Products: Summary of the Annual Report for 2025
Shenzhen Kangtai Biological Products: Annual Report 2025
Express News | Kangtai Bio: Bivalent Enterovirus Inactivated Vaccine Initiates Phase I Clinical Trial
CSC Financial: The phased production of biologics continues to advance, benefiting capacity optimization and efficiency improvement.
The Notice specifies regulatory requirements for the segmented production of biological products, establishing a comprehensive operational guideline. This notice comprises six provisions, offering provincial drug regulatory authorities a complete set of operational guidelines for segmented production licensing and oversight.
Shenzhen Kangtai Biological Products Gets China Clinical Trial Approval for DPT Jab
Kangtai Bio (300601.SZ): Tetanus Toxoid Vaccine Receives Drug Registration Certificate
Kangtai Bio (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd. (referred to as "Minhai Biotech"), has received the 'Drug Registration Certificate' issued by the National Medical Products Administration for its adsorbed tetanus vaccine developed today. The adsorbed tetanus vaccine is prepared by using tetanus toxoid adsorbed with an adjuvant. This vaccine is primarily intended for populations who are more prone to injuries, and pregnant women vaccinated with this product can prevent maternal and neonatal tetanus. Vaccination with this product stimulates the body to produce tetanus antibodies, thus preventing tetanus. Tetanus is a highly severe acute infectious disease caused by the invasion of Clostridium tetani through skin or mucosal wounds, followed by localized growth, reproduction, and toxin production within the wound.
CSC Financial: The batch release of vaccine industry products declined year-on-year in 2025, with multiple key products approved for market launch.
In 2025, the total number of batch releases in the vaccine industry reached 3,793 batches, representing an 11.3% year-on-year decrease. This decline was primarily driven by significant reductions in the number of batch releases for products such as polio vaccines, meningitis vaccines, encephalitis vaccines, and measles-mumps-rubella vaccines.
Kangtai Bio (300601.SZ): Shareholders Terminate Concert Party Relationship
Gelonghui, February 6th丨Kangtai Bio (300601.SZ) announced that it has received a notice from the company's controlling shareholder and actual controller, Mr. Du Weimin, stating that Ms. Yuan Liping, Hangzhou Hekun Enterprise Management Co., Ltd., and Shenzhen Qianhai Bopu Asset Management Co., Ltd. (representing its managed Bopu Zunxiang No. 1 Private Securities Investment Fund, Bopu Zunxiang No. 2 Private Securities Investment Fund, Bopu Zunxiang No. 3 Private Securities Investment Fund, Bopu Zunxiang No. 4 Private Securities Investment Fund, Bopu Zunxiang No. 5 Private Securities Investment Fund, Bopu Zunxiang No. 6 Private Securities Investment Fund, Bopu Zunxiang No. 7 Private Securities Investment Fund)
Kangtai Biotech (300601.SZ): Subsidiary awarded the second prize of Jiangsu Province Science and Technology Progress Award
Gelonghui, February 6th ┃ Kangtai Bio (300601.SZ) announced that Minhai Biotechnology Co., Ltd. (hereinafter referred to as 'Minhai Bio'), a wholly-owned subsidiary of the company, has been awarded the second prize of Jiangsu Province Science and Technology Progress Award for its significant participation in the project 'Technological Innovation and Application of Rapid Identification and Precision Prevention and Control of Emerging Viral Infectious Diseases.' This marks another major honor in the field of scientific and technological innovation for Minhai Bio after receiving the second prize of Beijing Science and Technology Progress Award and being approved as the Beijing Key Laboratory of Synthetic Immunology and Vaccine Intelligent Manufacturing. The project was led by the Jiangsu Provincial Center for Disease Control and Prevention and proposed by the Provincial Health Commission.
Kangtai Bio (300601.SZ): Major shareholder with over 5% stake increases concert parties and internally transfers shares among concert parties.
Gelonghui, February 6th: Kangtai Bio (300601.SZ) announced that due to personal asset planning needs, Ms. Yuan Liping, a shareholder holding more than 5% of the company's shares, intends to transfer a portion of the company’s shares held through her 100%-owned Bopu Private Fund product, up to 22.33 million shares (not exceeding 2.00% of the company’s total share capital), via block trading to the Huabao Wanying Private Fund product, which is considered her acting-in-concert party. This share transfer plan represents an internal transfer between the shareholder and her acting-in-concert party. The transferred shares will remain 100% owned by Ms. Yuan Liping and will not involve any reduction in holdings on the open market.